BEST-CLI试验中慢性肾脏病对慢性肢体威胁性缺血血运重建结局的影响
基于BEST-CLI随机试验数据,将1797例慢性肢体威胁性缺血患者按慢性肾脏病分期分为三组。C组(5期或透析依赖)较A组截肢风险翻倍(HR 2.13)、MALE或全因死亡风险翻倍(HR 2.05)、全因死亡风险增至三倍以上(HR 3.40)。透析依赖患者中腔内治疗生存更优但再干预风险为外科的兩倍。
要点
- C组(5期或透析依赖)较A组截肢风险HR 2.13、MALE或全因死亡HR 2.05、全因死亡HR 3.40,均P < .001
- eGFR <30较≥60的MALE风险HR 2.03(95%CI 1.68-2.43),死亡风险HR 3.46(95%CI 2.80-4.27)
- 透析依赖患者中腔内治疗生存更优但再干预风险为外科的兩倍
核心结论
- 慢性肢体威胁性缺血患者的肾功能进行性损害威胁其生存和保肢,并可能降低整体BEST-CLI试验人群中开放手术相对于腔内血运重建的相对获益。
- 透析依赖患者中,腔内治疗与较低死亡率相关但再干预率增加。
研究设计与样本
- 前瞻性随机BEST-CLI试验数据集分析,按慢性肾脏病分期将患者分为三组:A组为非慢性肾脏病及慢性肾脏病分期<3,B组为3期和4期,C组为5期和透析依赖。
- 对研究参与者观察到的eGFR范围进行样条建模以识别影响主要结局的eGFR阈值,主要结局为MALE或全因死亡,按外科或腔内血运重建进行as-treated分析。
- 采用Kaplan-Meier和多变量Cox回归分析评估慢性肾脏病风险组与结局的关联。
- 共纳入1797例患者。
主要发现
- C组较A组截肢风险HR 2.13(P < .001)、MALE或全因死亡风险HR 2.05(P < .001)、全因死亡风险HR 3.40(P < .001)。
- 透析依赖患者中,腔内治疗与更好生存相关,但再干预风险为外科血运重建的兩倍。
- 样条模型分析显示,eGFR <30时MALE或全因死亡风险急剧增加。
- eGFR <30 vs ≥60的MALE风险HR 2.03(95%CI 1.68-2.43;P < .001),死亡风险HR 3.46(95%CI 2.80-4.27;P < .001)。
- eGFR <30时,主要结局在接受外科或腔内血运重建之间无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic limb-threatening ischemia (CLTI) in patients with chronic kidney disease (CKD) has a high risk of poor outcomes. We aimed to compare the outcomes of lower extremity revascularization in patients with CLTI stratified by CKD severity in patients enrolled in the prospective, randomized Best Endovascular vs Best Surgical Therapy in Patients with CLTI (BEST-CLI) trial. METHODS: The BEST-CLI trial dataset was queried to categorize patients into three groups according to CKD stage. Group A includes non-CKD and CKD stages <3; group B includes stage 3 and stage 4 CKD patients; and group C includes stage 5 CKD and dialysis-dependent patients. Furthermore, spline modeling was performed across the range of estimated glomerular filtration rate (eGFR, mL/min/1.73 m2) observed in study participants to identify a threshold eGFR that impacted the primary trial outcomes: major adverse limb events (MALEs; defined as above-ankle amputation or major reintervention) or all-cause mortality, by surgical or endovascular revascularization (as-treated analysis). Kaplan-Meier and multivariate Cox regression analyses were used to assess association of CKD risk groups with the outcomes. RESULTS: A total of 1797 patients were included. Group C patients had double the risk of amputation (hazard ratio [HR], 2.13; P < .001), MALE, or all-cause mortality (HR, 2.05; P < .001) and more than triple the risk of all-cause mortality (HR, 3.40; P < .001) compared with group A. In dialysis-dependent patients, endovascular therapy was associated with better survival, but twice the risk of reintervention compared with surgical revascularization. According to spline model analysis, hazard of MALE or all-cause mortality increased sharply at eGFR <30. The hazard ratios for eGFR <30 vs ≥60 were 2.03 (95% confidence interval [CI], 1.68-2.43; P < .001) and 3.46 (95% CI, 2.80-4.27; P < .001) for MALE and mortality, respectively. At eGFR <30, there was no difference in the primary outcome by treatment received (surgical or endovascular revascularization). CONCLUSIONS: The progressive nature of renal impairment in patients with CLTI threatens their survival and limb salvage and may reduce the relative benefit of open vs endovascular revascularization seen in the overall BEST-CLI trial population. In dialysis-dependent patients, endovascular therapy was associated with lower mortality but increased reintervention rate.
引用
- Malas MB, Hamouda M, Farber A, et al. Outcomes of chronic limb-threatening ischemia revascularization in patients with chronic kidney disease in the BEST-CLI trial. J Vasc Surg. 2025. PMID: 39846933. doi:10.1016/j.jvs.2024.12.128
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。